We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Ovarian Cancer Protein Contributes to Alzheimer`s Disease Neurodegeneration

By LabMedica International staff writers
Posted on 30 Jan 2020
Print article
Image: In the brain of mice with Alzheimer\'s, areas near amyloid plaques (A) appear with fewer neural networks (B), dying neurons (C) and higher OCIAD1 (D). In cultured neuronal cells, the OCIAD1 proteins (E) appear in the mitochondria (F) (Photo courtesy of Houston Methodist Research Institute).
Image: In the brain of mice with Alzheimer\'s, areas near amyloid plaques (A) appear with fewer neural networks (B), dying neurons (C) and higher OCIAD1 (D). In cultured neuronal cells, the OCIAD1 proteins (E) appear in the mitochondria (F) (Photo courtesy of Houston Methodist Research Institute).
Alzheimer's disease is a complex neurological disorder with pathological hallmarks of hyperamyloidosis (senile plaques), neurofibrillary tangles containing hyperphosphorylated tau, and extensive neurodegeneration in the brain.

Alzheimer's disease (AD) pathogenesis remains elusive and no effective therapy is available. Neurodegeneration, including synaptic damage and neuronal loss, forms the basis of dementia in AD, and certain brain regions are more vulnerable during disease progression.

Scientists at the Houston Methodist Research Institute (Houston, TX, USA) and their colleagues reported on a new role of ovarian cancer immune-reactive antigen domain containing 1 (OCIAD1). Originally discovered for its effect on ovarian cancer metastasis and stem cell metabolisms, the group found the OCIAD1 protein in human brain cells, and determined it impairs neurons and damages synapses in the brain, contributing to neurodegeneration in Alzheimer's disease.

The investigators culled through archived bioinformatics data of brain tissue from deceased Alzheimer's patients, as well as mouse models by blending computational methods with laboratory studies. They determined that OCIAD1 plays a role in the disease's progressive neurodegeneration by impairing mitochondria function. Known as the powerhouse of cells, damage to mitochondria results in the trickle-down cell death effect in the brain leading to neuron damage.

Higher levels of OCIAD1, found in vulnerable brain areas and dystrophic neurites, were correlated with disease severity. Multiple early AD pathological events, particularly Aβ/GSK-3β signaling, elevated OCIAD1, which in turn interacts with BCL-2 to impair mitochondrial function and facilitates mitochondria-associated neuronal injury. Notably, elevated OCIAD1 by Aβ increases cell susceptibility to other AD pathological challenges.

Xuping Li, PhD, an instructor of Neurodegeneration in Oncology and co-corresponding author, said, “We applied a system biology strategy to see if we could find a different mechanism of neurodegeneration in Alzheimer's disease. We identified OCIAD1 as a new neurodegeneration-relevant factor, predicted its function, and demonstrated it mediates the long-term impact of amyloid beta on cells and synaptic damages by impairing mitochondria function.” The study was published on January 12, 2020 in the journal EBioMedicine.

Related Links:
Houston Methodist Research Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.